 |
BioWorld-Insight-2003-01-27
Money Raised Year To Date
Avant: Case Study Of A Defense Deal Helping Keep Firms Healthy
Some cynical Europeans might snicker about industry in America profiting from a threatened terrorist siege. Other commentators may marvel instead at company scientists' ability to engineer biodefense weapons. The editorial-page beat goes on.